West Pharmaceutical Services, Inc.
WST
$230.11
$6.382.85%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 748.80M | 746.90M | 702.10M | 695.40M | 732.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 748.80M | 746.90M | 702.10M | 695.40M | 732.00M |
| Cost of Revenue | 475.20M | 482.20M | 472.10M | 465.20M | 453.90M |
| Gross Profit | 273.60M | 264.70M | 230.00M | 230.20M | 278.10M |
| SG&A Expenses | 83.30M | 81.90M | 83.00M | 86.70M | 90.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 0.00 | 600.00K | -- | 300.00K | 1.00M |
| Total Operating Expenses | 577.00M | 580.20M | 572.60M | 569.80M | 564.00M |
| Operating Income | 171.80M | 166.70M | 129.50M | 125.60M | 168.00M |
| Income Before Tax | 166.90M | 168.40M | 133.20M | 131.70M | 171.50M |
| Income Tax Expenses | 36.80M | 32.40M | 21.90M | 16.40M | 34.50M |
| Earnings from Continuing Operations | 130.10M | 136.00M | 111.30M | 115.30M | 137.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 130.10M | 136.00M | 111.30M | 115.30M | 137.00M |
| EBIT | 171.80M | 166.70M | 129.50M | 125.60M | 168.00M |
| EBITDA | 212.50M | 206.90M | 168.40M | 161.20M | 203.90M |
| EPS Basic | 1.79 | 1.87 | 1.52 | 1.57 | 1.85 |
| Normalized Basic EPS | 1.52 | 1.46 | 1.15 | 1.13 | 1.46 |
| EPS Diluted | 1.78 | 1.85 | 1.51 | 1.55 | 1.82 |
| Normalized Diluted EPS | 1.51 | 1.45 | 1.14 | 1.12 | 1.44 |
| Average Basic Shares Outstanding | 72.70M | 72.80M | 73.00M | 73.50M | 74.10M |
| Average Diluted Shares Outstanding | 73.30M | 73.40M | 73.70M | 74.30M | 75.00M |
| Dividend Per Share | 0.21 | 0.20 | 0.20 | 0.20 | 0.20 |
| Payout Ratio | 11.76% | 10.66% | 13.12% | 12.75% | 10.80% |
